Literature DB >> 27723629

GSTM1 null polymorphism prevalence in tobacco users, oral leukoplakia and oral squamous cell carcinoma patients in South Indian population: A polymerase chain reaction study.

Renu Tanwar1, Asha R Iyengar2, K S Nagesh2, Seema Patil2, B V Subhash2.   

Abstract

CONTEXT: Tobacco abuse is a well-known risk factor for potentially malignant disorders as well as oral squamous cell carcinoma. Factors that influence tobacco-exposed individuals developing a malignancy may include the combination of total tobacco exposure and genetic susceptibility. AIM: This study was undertaken to determine the prevalence of the glutathione S-transferase M1 (GSTM1) null polymorphism in oral leukoplakia and oral squamous cell carcinoma patients in South Indian population. SETTINGS AND
DESIGN: This case-control study was conducted in hospital setting on South Indian population.
MATERIALS AND METHODS: About 280 subjects with history of tobacco use, oral leukoplakia, oral squamous cell carcinoma were included in this study. Three milliliter of blood was collected and transported under cold cycle and taken for evaluation of GSTM1 null polymorphism using multiplex polymerase chain reaction. RESULTS AND DISCUSSION: On comparing the prevalence of GSTM1 null polymorphism among the group with subjects with habits and no oral lesions, oral leukoplakia, and oral squamous cell carcinoma, it was observed that there was a statistically significant association between GSTM1 null polymorphism and the different groups (P < 0.01).
CONCLUSION: The lack of GSTM1 activity would make the oral tissues more susceptible to action of tobacco carcinogens and to the development of a high-grade level of dysplasia in oral leukoplakia and thereby increases the susceptibility of lesion to undergo malignant changes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27723629     DOI: 10.4103/0970-9290.191881

Source DB:  PubMed          Journal:  Indian J Dent Res        ISSN: 0970-9290


  1 in total

Review 1.  Glutathione S-transferase π: a potential role in antitumor therapy.

Authors:  Shu-Chen Dong; Huan-Huan Sha; Xiao-Yue Xu; Tian-Mu Hu; Rui Lou; Huizi Li; Jian-Zhong Wu; Chen Dan; Jifeng Feng
Journal:  Drug Des Devel Ther       Date:  2018-10-23       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.